Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer.
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To assess the antitumour activity (response rate) in patients with locally advanced or
metastatic non-small cell lung cancer (NSCLC) of two different combinations of docetaxel and
gemcitabine and of a sequential treatment of cisplatin /gemcitabine followed by docetaxel as
first line chemotherapy · To evaluate the quantitative and qualitative toxicity of each
treatment arms.· To determine time to progression, duration of response, time to treatment
failure, and overall survival in each group.· To evaluate changes from baseline in the Lung
Cancer Symptom Scale of patients in each treatment arm.